Booming Clinical Trials Market in India

Date: August 22, 2011
Pages: 145
Price:
US$ 1,000.00
Publisher: RNCOS E-Services Pvt. Ltd.
Report type: Strategic Report
Delivery: E-mail Delivery (PDF), Hard Copy Mail Delivery, CD-ROM Mail Delivery
ID: B4D4AAFEF72EN
Leaflet:

Download PDF Leaflet

Booming Clinical Trials Market in India
Single User PDF Format: US$ 1,000.00
Multi-User License: US$ 1,600.00
Hard Copy: US$ 1,200.00
CD-ROM: US$ 1,200.00


India has billion plus population and a home for various life threatening diseases. These factors provide an opportunity for global medical practitioners and healthcare providers to consider India as an effective destination for research and clinical studies. India has registered fast growth in the number of clinical trials over the past few years, reflecting that the country has become one of the most attractive destinations for medical research.

According to our new research report, “Booming Clinical Trials Market in India”, the number of clinical studies by domestic and global players has sharply risen. The M&A activities, service agreements, and strategic collaboration have increased over the last four years. The majority of the deals in the contract research organizations market focused on establishing strategic alliances with other contract research organizations, technology providers, and pharmaceutical and biotech companies. In addition, on the back of favorable government support and effective regulatory mechanism provided by the ICMR and CDSCO, healthcare providers find it worthwhile to locate their trials in India. Besides, availability of skilled manpower and good medical infrastructure will augment the number of clinical trials from 1300 in 2009 to more than 1900 by 2013.

We have analyzed the Indian clinical trial market with emphasis on current market trends and future outlook. Our report has found that with the rising participation of private players and improvement in the number of medical professionals, new avenues of research will be developed in the country. All these factors will facilitate market development and boost market growth in future. A large number of patients for clinical trials are expected to strengthen the market even more.

Our study indicates that, India, over the last decade, has developed significant capabilities in clinical trials, along with certain capabilities in project management and data management. India is able to provide significant cost savings of 50-60% for clinical trials. With discovery research occupying close to one-third of the R&D expenditure for the western pharmaceutical industry, outsourcing to low-cost countries is logical. As the financial and regulatory pressure grows on the US and European pharmaceutical industry, it is expected to further propel the growth in the Indian clinical trial market.

Our report is an outcome of extensive research and prudent analysis of the Indian clinical trial market. The report covers all the necessary segments of the sector, providing reliable and latest data of the industry. The report also presents future outlook of different areas. Moreover, the description of key players and their recent activities have been covered in the report.
1. ANALYST VIEW

2. RESEARCH METHODOLOGY

3. CLINICAL TRIALS MARKET OVERVIEW

3.1 Clinical Trials Market
3.2 Clinical Trials by Type
3.3 Number of Clinical Trials
3.4 State-wise Trials

4. GROWTH FACILITATORS AND EMERGING TRENDS

4.1 Cost Competitiveness in Conducting Clinical Trials
4.2 Faster Completion of Clinical Trials
4.3 Government Support
4.4 Clinical Data Management: Demand of the Hour
4.5 Pharma Outsourcing Market
4.6 Pathology and Diagnostic Market

5. SIZE AND PATIENT POOL AVAILABILITY

5.1 Demographics Profile
5.2 Disease Profile
5.3 Patient Availability and Recruitment

6. INFRASTRUCTURE AND EXPERTISE

7. BUSINESS OUTSOURCING MODELS FOLLOWED BY PLAYERS

8. PROCEDURE FOR CONDUCTING CLINICAL TRIALS

9. REGULATORY ENVIRONMENT

10. INDUSTRY BOTTLENECKS AND PRECAUTIONS

11. COST ANALYSIS FOR CLINICAL TRIALS

11.1 Total Budget Cost
11.2 Cost Comparison with US
11.3 Cost Analysis by Phases
  11.3.1 Phase I (Cost of Utility and Staff)
  11.3.2 Phase II (Cost of Utility and Staff)
  11.3.3 Phase III (Cost of Utility and Staff)
  11.3.4 Phase IV (Cost of Utility and Staff)

12. COMPETITIVE LANDSCAPE

12.1 Overview
12.2 Competitive Landscape
  12.2.1 Veeda Clinical Research
  12.2.2 SIRO Clinpharm Private Limited
  12.2.3 Sipra Labs Limited
  12.2.4 Clintrac International
  12.2.5 Clinigene International
  12.2.6 Quintiles India
  12.2.7 Synchron Research Services
  12.2.8 Max Neeman International
  12.2.9 DiagnoSearch Life Sciences
  12.2.10 Vimta Labs
  12.2.11 Lambda Therapeutic Research
  12.2.12 Ecron Acunova

LIST OF FIGURES:

Figure 3-1: Clinical Research Outsourcing Market (Million US$), 2009-2015
Figure 3-2: Clinical Trials by Phase (%)
Figure 3-3: Clinical Trials by Therapy (%)
Figure 3-4: Clinical Trials by Funding (%)
Figure 3-5: Number of Global and Local Trials Permitted (2007-2010)
Figure 3-6: Number of Clinical Trials (2007 & 2009)
Figure 4-1: Average Annual Cost for Conducting Clinical Trials in Comparison to US
Figure 4-2: Investigator Cost per Visit in Comparison to US, UK and Singapore
Figure 4-3: Numbers of Clinical Trials Completed on Time in Comparison to UK, US and Germany
Figure 4-4: Time Taken for Conducting Clinical Trials by Phase in Comparison to US (Months)
Figure 4-5: Pharma Outsourcing Market (Billion US$), 2009-2013
Figure 4-6: Pharma Outsourcing Market by Segment (%), 2008
Figure 4-7: IVD Market (Million US$), 2009 & 2012
Figure 5-1: Population (Million), 2009-2013
Figure 5-2: Population Breakup by Age Group (%), 2009-2013
Figure 5-3: New and Total Number of Cancer Patients (‘000)
Figure 5-4: Number of Hypertension Patients (Million), 2009 & 2025
Figure 5-5: Number of Coronary Heart Disease Patients (Million), 2010 & 2015
Figure 5-6: Recruitment Time for Patients Participating in Clinical Trials in Comparison to US (Days)
Figure 5-7: Number of Patient per Site in Comparison to US
Figure 6-1: Annual Supply of Science Graduates and Postgraduates (‘000)
Figure 6-2: Number of Graduates and Postgraduates (Million), 2004
Figure 6-3: Share of Science Doctorates in Total Doctorates (2004)
Figure 6-4: Number of Doctors in Comparison to US and Germany (per ‘000 Population), 2009
Figure 6-5: Demand-Supply Gap in Clinical Research Professionals (Number), 2010
Figure 6-6: Number of GCP Trained Investigators (2002 & 2005)
Figure 6-7: Number of GCP Trained Investigators in Comparison to US
Figure 6-8: Number of Hospital Beds (‘000), 2009-2013
Figure 6-9:Hospital Beds Density of Key Countries (per ‘000 Population), 2010
Figure 6-10: Number of Industry Sponsored Phase II-III Clinical Trial Sites of Key Countries
Figure 11-1: Average Cost per Patient for Conducting Clinical Trials in Comparison to UK, US and Germany (US$)
Figure 11-2: Average Cost per Patient for Conducting Phase I Clinical Trials in Comparison to UK, US and Germany (US$)
Figure 11-3: Average Cost per Patient for Conducting Phase II Clinical Trials in Comparison to UK, US and Germany (US$)
Figure 11-4: Annual Cost of Office Space for Conducting Phase II Clinical Trials in Comparison to UK, US and Germany (US$)
Figure 11-5: Average Cost per Patient for Conducting Phase III Clinical Trials in Comparison to UK, US and Germany (US$)
Figure 11-6: Annual Cost of Office Space for Conducting Phase III Clinical Trials in Comparison to UK, US and Germany (US$)
Figure 11-7: Average Cost per Patient for Conducting Phase IV Clinical Trials in Comparison to UK, US and Germany (US$)
Figure 11-8: Annual Cost of Office Space for Conducting Phase IV Clinical Trials in Comparison to UK, US and Germany (US$)

LIST OF TABLES:

Table 3-1: Details of State-wise Clinical Trials (January-July 2011)
Table 4-1: Features of Clinical Trials in Comparison to US
Table 5-1: Number of Deaths due to Leading Causes in Middle Income Countries (Million)
Table 5-2: Number of Diabetic Patients in Age Group 20-79 (‘000), 2010
Table 5-3: Forecast for Number of Diabetic Patients in Age Group 20-79 (‘000), 2030
Table 5-4: New Cancers Incidences (per ‘00,000 Females), 2005
Table 5-5: New Cancers Incidences (per ‘00,000 Males), 2005
Table 5-6: Obesity Statistics (2009)
Table 6-1: Structure of Medical Education
Table 6-2: Number of GLA Approved Facilities by Type
Table 9-1: Regulatory Bodies Involved in Pharmaceutical Regulation
Table 9-2: Regulatory Timelines for Conducting Clinical Trials
Table 11-1: Average Cost of Clinical Research in Comparison to US by Phase (Million US$)
Table 11-2: Calculation of Clinical Trials Costs Savings in Comparison to US
Table 11-3: Annual Cost of Staff for Conducting Phase I Clinical Trials in Comparison to UK, US and Germany (US$)
Table 11-4: Annual Cost of Utility for Conducting Phase I Clinical Trials in Comparison to UK, US and Germany (US$)
Table 11-5: Annual Cost of Staff for Conducting Phase II Clinical Trials in Comparison to UK, US and Germany (US$)
Table 11-6: Annual Cost of Utility for Conducting Phase II Clinical Trials in Comparison to UK, US and Germany (US$)
Table 11-7: Annual Cost of Staff for Conducting Phase III Clinical Trials in Comparison to UK, US and Germany (US$)
Table 11-8: Annual Cost of Utility for Conducting Phase III Clinical Trials in Comparison to UK, US and Germany (US$)
Table 11-9: Annual Cost of Staff for Conducting Phase IV Clinical Trials in Comparison to UK, US and Germany (US$)
Table 11-10: Annual Cost of Utility for Conducting Phase IV Clinical Trials in Comparison to UK, US and Germany (US$)
Skip to top


Clinical Trials Market in India 2012 US$ 795.00 Apr, 2012 · 58 pages
Clinical Trials: World Market 2010-2025 US$ 2,325.00 Jul, 2010 · 138 pages
CNS Clinical Trials: World Market Prospects 2011-2026 US$ 2,325.00 Dec, 2010 · 165 pages

Ask Your Question

Booming Clinical Trials Market in India
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: